Small‐Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions
Ischemic heart disease (IHD), stroke, and dementia are leading causes of death and disability worldwide,1, 2 notably affecting aging populations. The public health burden related to chest pain is substantial and the epidemiology of IHD because of large‐vessel coronary atherosclerosis is well documented.2 By contrast, the epidemiology of small‐vessel disease (SVD) in the heart is less well established.3, 4 Cohort studies indicate that the underlying cause of anginal chest pain may be SVD in more than 1 in 3 of all‐comers with stable symptoms.3, 4 IHD because of SVD associates with vascular risk factors, such as hypertension and female sex.3, 4, 5, 6
The vascular anatomy of the heart and brain is similar in that conduit arteries are distributed on the surface of these organs with tissue perfusion achieved through deep penetrating arteries. In the heart, SVD involves the deep penetrating coronary arterioles and the subendocardial plexus of microvessels.7 The clinical sequelae of SVD in the heart include stable and acute coronary syndromes and heart failure in the longer term.3, 4 SVD in the brain mainly involves small subcortical cerebral arteries. Occlusion of 1 of these vessels may result in a clinical stroke syndrome known as a lacunar syndrome. Acute imaging may show a lesion (<20 mm) on diffusion‐weighted magnetic resonance imaging (MRI) indicating an acute lacunar infarct. Later imaging may continue to identify the resulting end‐stage lesion as a lacune (<15 mm). Long‐term ischemia from SVD may show only white matter hyperintensities with or without lacunes and may manifest as vascular cognitive impairment.8, 9 SVD may manifest as a multisystem disorder10 implying commonality between disorders of small vessels of the heart and brain (and potentially other organs such as the kidney) (Figure 1).
In this article, we review the co‐existence of SVD in heart and brain. We consider evidence for and against a pathophysiological link between SVD in the heart and brain. We identify gaps in knowledge and disease‐modifying therapy. Clinical cases are presented in Figure 2.
Methods
We undertook a literature search for original research articles including information on SVD in both heart and brain. The search used PubMed and covered the period January 1, 1973 to May 31, 2018. We searched for Human studies in English that included these terms in the Title or Abstract (small‐vessel disease, microvascular, arteriolar, arteriole, arteriolosclerosis, leukoaraiosis) AND (heart, cardiac, cardiol, myocardial, myocardium, angina, Syndrome X) AND (Brain, cerebral, cerebrovascular). This search yielded 513 hits and 2 researchers (N.S., A.C.P.) independently screened the abstracts. Eighteen abstracts were selected and the outputs were discussed by 4 investigators (N.S., A.C.P., C.B., and A.H.H.). By consensus, we identified 9 research articles that provided information on SVD in both the heart and the brain, and 1 other on microvascular disease in the kidney and brain. The search was updated on October 12, 2018 and no new original articles fulfilling these criteria were identified. The totality of evidence was insufficient to support a meta‐analysis. The articles that are included in this review11, 12, 13, 14, 15, 16, 17, 18, 19 are summarized in Table 1. The articles that are not included are summarized in Table S1.
| Authors/Y | Organ | Design | Objective | Focus | n | Key Findings |
|---|---|---|---|---|---|---|
| Brunelli et al 199611 | Brain & heart SVD | Descriptive study | Measure the cerebral blood flow and cerebrovascular vasodilator reserve in patients with coronary microvascular dysfunction and in controls | Patients with coronary microvascular dysfunction | 16 | Cerebral blood flow and cerebrovascular vasodilator reserve were preserved in a series of patients with coronary microvascular dysfunction, which is not consistent with the hypothesis of a diffuse smooth‐muscle disorder |
| Sun et al 200112 | Brain & heart SVD | Case–control study | Investigate whether coronary microvascular dysfunction is a systemic vascular disorder | Patients with coronary microvascular dysfunction | 40 | 23/25 cases with definite myocardial perfusion defects diagnosed by thallium‐201 myocardial perfusion SPECT also had multiple hypoperfusion areas in the brain vs 2/15 patients without thallium myocardial defects. The parietal lobes were the most common hypoperfusion areas, and cerebellum was the least common |
| Lesnik Oberstein et al 200313 | Brain & heart SVD | Descriptive study | Determine whether myocardial ischemia is associated with NOTCH3 mutations | Members of 15 unrelated families with CADASIL | 63 | NOTCH3 mutations associated with myocardial ischemia (10 patients with evidence of MI—5 silent); MI predates neurological symptoms (5 patients with MI) and coronary angiography (4 patients) showed unobstructed coronaries; 1 pathology study—myocardial tissue showed no macroscopic stenosis but abnormal microvasculature |
| Pai et al 200314 | Brain & heart SVD | Case–control study | Investigate whether coronary microvascular dysfunction is a systemic vascular disorder | Patients with coronary microvascular dysfunction | 30 | Coronary microvascular dysfunction is a systemic vascular disorder with a high incidence of hypoperfusion lesions of the brain based on the findings of Tc‐99m ECD brain SPECT, and is usually coincident with myocardial defects based on the Tl‐201 myocardial perfusion SPECT findings |
| Andin et al 200515 | Cardiac & neuropathology | Postmortem examination of patients in prospective, longitudinal study | Cardiovascular pathology in different types of vascular dementia; Relationship between cardiovascular & cerebrovascular disorders and type of vascular dementia | Prospective, longitudinal study of dementia | 175 | MI and hypertension in men are associated with small‐vessel dementia; coronary/aortic arteriosclerosis and MI more common in this group (than large‐vessel dementia/multi‐infarct dementia/hypoperfusive hypoxic–ischemic dementia) |
| Thore et al 200716 | Brain SVD | Descriptive neuropathology study | Determine an association between arteriolar tortuosity and leukoaraiosis | Autopsy cases | 55 | Arterial tortuosity in human cerebral white matter associates with coronary artery disease (the presence of vascular stenosis, either coronary or cerebrovascular, displayed the highest correlation with tortuosity (P=0.0582), almost reaching significance) |
| Park et al 201317 | Brain & heart SVD | Case report | Description of cardiac investigations in a patient with CADASIL | ··· | 1 | Myocardial SPECT showed reversible perfusion defects in the septum (possibly because of vascular disease in the septal perforators of the LAD) |
| Riverol et al 201518 | Brain & kidney SVD | Prospective cohort study | Determine whether SVD in the kidney can predict SVD in the brain | Baseline brain MRI and cystatin C levels and no history of dementia | 735 | Higher cystatin C levels are associated with more WMLs, lower GM volume, and poorer cognitive function 6 y later (is this because of common SVD process or does CKD lead to brain SVD?) |
| Yamamoto et al 201319 | Brain & systemic (skin) SVD | Descriptive immunochemistry and electron microscopy study | Examine the specific N3ECD accumulation in relation to GOM in the cerebral vasculature and brain parenchyma of CADASIL patients and compared findings with other non‐CADASIL hereditary and sporadic SVD of the brain | Patients with CADASIL, non‐CADASIL hereditary SVD and sporadic age‐related degenerative disease, and comparable‐age controls | 75 | N3ECD is predominantly localized within GOM deposits and the extensive distribution of N3ECD‐GOM complexes within meninges, arteries, arterioles, and brain capillaries of CADASIL patients suggests NOTCH3 fragments are major components of GOM deposits, which may be eliminated via perivascular routes |
John Wiley & Sons, Ltd
Publications are listed in chronological order. CADASIL indicates cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CKD, chronic kidney disease; ECD,; GM, gray matter; GOM, granular osmiophilic material; LAD, left anterior descending artery; MI, myocardial infarction; N3ECD, NOTCH3 extracellular domain protein; SPECT, single‐photon emission computed tomography; SVD, small‐vessel disease; WMLs, white matter lesions.
SVD in the Heart—Microvascular Angina
SVD in the heart was historically referred to as “Cardiac Syndrome X.” 3, 4 This term has been superseded by the more appropriate term microvascular angina (MVA). Symptoms in affected patients may be triggered by exertion, emotional stress, cold weather, the menstrual cycle, and menopause.4 Structural microvessel abnormalities, extravascular compressive forces, and abnormal coronary microvascular tone may be underpinning mechanisms leading to MVA.4 The diagnostic criteria for MVA have been recently proposed by the COVADIS (Coronary Vasomotion Disorders International Study) steering group (Table 2).20
| Clinical criteria for suspecting MVAa |
1 Symptoms of myocardial ischemia a. Effort and/or rest angina b. Angina equivalents (i.e., shortness of breath) 2 Absence of obstructive CAD (b = >50% diameter reduction or FFR N = ≤0.80) by a. Coronary CTA b. Invasive coronary angiography 3 Objective evidence of myocardial ischemia a. Ischemic ECG changes during an episode of chest pain b. Stress‐induced chest pain and/or ischemic ECG changes in the presence or absence of transient/reversible abnormal myocardial perfusion and/or wall motion abnormality 4 Evidence of impaired coronary microvascular function a. Impaired coronary flow reserve (cutoff values depending on methodology use between ≤2.0 and ≤2.5) b. Coronary microvascular spasm, defined as reproduction of symptoms, ischemic ECG shifts but no epicardial spasm during acetylcholine testing. c. Abnormal coronary microvascular resistance indices (e.g., IMR >25) d. Coronary slow flow phenomenon, defined as TIMI frame count >25. |
John Wiley & Sons, Ltd
CAD indicates coronary artery disease; CTA, computed tomographic angiography; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; MVA, microvascular angina; TIMI, thrombolysis in myocardial infarction.
a
Definitive MVA is only diagnosed if all 4 criteria are present for a diagnosis of MVA. Suspected MVA is diagnosed if symptoms of ischemia are present (criterion‐1) with no obstructive coronary artery disease (criterion‐2) but only (a) objective evidence of myocardial ischemia (criterion‐3), or (b) evidence of impaired coronary microvascular function (criterion‐4) alone.
Invasive coronary angiography is the key test for the diagnosis and treatment of coronary artery disease. However, since the diameter of coronary microvessels is typically <0.5 mm, they are too small to be resolved visually by the cardiologist. Therefore, angiography is primarily an investigation for large artery coronary disease, and only a subset (40–50%) of patients undergoing coronary angiography have obstructive disease identified.21, 22 Building on these studies, in the recent British Heart Foundation Coronary Microvascular Angina (CorMicA) trial, 185 of 391 (47%) patients with angina undergoing clinically‐indicated elective coronary angiography during a 12‐month period had no obstructive coronary artery disease when assessed using invasive coronary angiography and fractional flow reserve. SVD was identified in 134 (89%) of 151 patients who had invasive measurement of coronary vascular function. This result points to the high prevalence of SVD in patients with ischemia and no obstructive coronary disease (INOCA).23 The coronary slow‐flow phenomenon may be disclosed by angiography in a subset of patients with INOCA (Table 2). Patients with INOCA may have impaired health‐related quality of life comparable to that of patients with obstructive coronary artery disease,22 and prognosis may be affected.3, 4, 22, 23, 24 Compared with population‐matched controls, patients with INOCA have almost double the risk of death, myocardial infarction, and stroke over a 7.5‐year period.25
Establishing the correct diagnosis in the catheter laboratory is a patient‐centered approach. Since coronary angiography alone may be insufficient, SVD‐specific tests of coronary function should be considered in selected patients with INOCA. Invasive tests of microvascular function include a diagnostic guidewire to measure microvascular resistance directly and coronary flow reserve and/or intracoronary infusion of acetylcholine. In current cardiological practice, these are rarely used. The reasons are multifactorial. Lack of evidence from randomized controlled trials and inadequate education and training of physicians are relevant.4, 26, 27 The CorMicA trial23 has reduced this gap in evidence. For the first time, CorMicA provided proof‐of‐concept evidence that a management strategy involving routine use of coronary function tests at the time of invasive coronary angiography in patients with INOCA improved symptoms and quality of life, compared with standard management guided by coronary angiography. These results support a stratified medical approach involving specific tests for SVD with linked therapy. Overall, more education and research are needed to improve patient‐centered management.
SVD of the Brain
Cerebral SVD (referred to in older literature as lipohyalinosis, Binswanger disease, subcortical leukoencephalopathy)8, 25 may manifest clinically as stroke (infarction) or a cognitive syndrome usually with executive dysfunction (because of subcortical white matter disruption or atrophy). Cerebral SVD is the primary cause of lacunar ischemic stroke, which represents ≈20% of all stroke. It appears to be the most common source of vascular contributions to cognitive impairment and dementia.24
Cerebral SVD encompasses a range of vascular pathologies including arteriolosclerosis, small‐vessel atheroma, and cerebral amyloid angiopathy as reviewed elsewhere.9, 28 Most prevalent is arteriolosclerosis, or “simple” SVD, which is a concentric hyaline thickening of deep penetrating small arteries (outer diameter <200 μm) with fibrosis of the vessel wall and depletion of vascular smooth muscle cells.9 This is detected as diffuse white matter hyperintensities on T2‐weighted MRI, associated with small focal ischemic lesions in subcortical areas, sometimes accompanied by microbleeds and, more rarely, deep intracerebral hemorrhage. While age and hypertension are strong risk factors, the molecular mechanisms in cerebral SVD are little known. Systematic review and meta‐analyses have suggested that white matter hyperintensities (indicative of underlying SVD) are associated with an increased risk of dementia (hazard ratio 1.9),28 whereas prospective population‐based data indicate that white matter hyperintensities are associated with 1.4‐fold increased risk of dementia.9, 28, 29
Vascular aging shares some pathophysiological features seen in hypertensive vascular disease. In the Atherosclerosis Risk in Communities prospective cohort study of 1827 participants age 45 to 64 years drawn from 4 regions in the United States,30 small lacunes defined as focal lesions hyperintense to gray matter on both proton density and T2‐weighted MRI were independently associated with age (per year: 1.12 [1.45–2.02]) and other vascular risk factors including hypertension (2.11 [1.50–2.97]), diabetes mellitus (1.34 [0.95–1.90]), and ever‐smoking (1.47 [1.06–2.03]).
Possible Genetic Link Between Heart and Brain SVD
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a familial genetic form of cerebral SVD caused by mutations in the NOTCH3 gene, which is expressed in vascular smooth muscle cells.13, 15, 17, 31 The pathological hallmark is deposition of granular osmophilic deposits in vascular smooth muscle cells. Radiologically and pathologically, it presents as a severe form of SVD with younger age of onset (usually before aged 50 years) and little hypertension dependence, relative to sporadic SVD. While CADASIL classically affects brain vessels, it has the potential for systemic changes in the microcirculation.22 Lesnik Oberstein et al13 first reported myocardial infarction as an incidental finding in a case series of patients with genetically confirmed CADASIL (Table 1). Using a core laboratory approach, they evaluated the ECGs of 15 unrelated families who had genotyping to rule‐in (n=41; mean age 46 years, 19 [46% men]) or rule‐out (n=22; mean age 40 years, 10 [45% men]) the NOTCH3 mutation. They found ECG evidence of myocardial infarction in 10 of 41 mutation carriers while none of the 22 nonmutation carriers had any ECG evidence of myocardial infarction. Cardiac pathology in one deceased NOTCH3 mutation carrier revealed minimal atherosclerosis in the coronary arteries, whereas microvessels exhibited irregular fibrosis and elastosis of the media. Park et al17 reported the case history of a 46‐year‐old woman who had CADASIL and who was hospitalized following a stroke. Brain MRI revealed severe ischemic white matter changes and multiple chronic infarcts. The ECG revealed poor R‐wave progression and subsequent stress‐rest 99mTc‐tetrofosmin myocardial perfusion single photon emission computed tomography (SPECT) revealed reversible myocardial perfusion defects in the distribution of the left anterior descending coronary artery. Computed tomography coronary angiography excluded coronary artery disease, supporting a diagnosis of coronary SVD.
Evidence Linking SVD in the Heart and Brain
In a clinical–pathological series of 175 cases described as “vascular dementia,” Andin et al15 found that cardiac pathologies were more prevalent in patients with pathological evidence of cerebrovascular SVD (characterized by subcortical lacunes) than in other vascular dementia groups (subtyped in their report as large‐vessel dementia, hypoperfusive, hypoxic–ischemic dementia, venous infarct dementia, and hemorrhagic dementia).15
In a population study of 735 cognitively normal adults 65 years and older, the Cardiovascular Health Study‐Cognition Study, Riverol et al17 demonstrated that renal glomerular dysfunction correlated with cerebral SVD. Serum cystatin C concentration, taken to represent renal SVD, was associated with lower neuropsychological tests scores, the presence of MRI‐identified brain infarcts, and the volume of white matter lesions.18 Age, waist circumference, hypertension, reduced physical activity, cigarette smoking, and C‐reactive protein were all multivariate correlates of cystatin C concentration.18 These results provide evidence that SVD may be a systemic disorder, potentially more pronounced in patients with multimorbidity, and that shared vascular risk factors are relevant.32
Three case series have found evidence of a high prevalence of abnormalities in cerebral blood flow in patients with cardiac SVD.12, 14, 33 Weidmann et al33 studied cerebral blood flow using technetium‐99m (Tc‐99m)‐d,l‐hexamethylpropyleneamineoxime SPECT in a consecutive series of 95 patients (mean age 55 years) with MVA. They found that 72 (76%) had an abnormal brain SPECT scan, with hypoperfusion lesions in the parietal lobes predominating. Sun et al12 reported similar findings (Table 1). Pai et al14 found that in a group of 30 patients with cardiac SVD, brain hypoperfusion lesions on technetium‐99m ethyl cysteinate dimer brain SPECT were common (21/30 patients) and positively associated with the presence and extent of abnormalities in myocardial perfusion as revealed by thallium‐201 myocardial perfusion SPECT. Brunelli et al11 studied cerebral blood flow using 133Xe inhalation and found no differences between 16 patients with MVA and 16 controls. None of these studies included repeated assessments over time, and more research into the natural history of heart and brain SVD seems justified. Taken together, these studies show that heart and brain hypoperfusion may co‐exist in patients with MVA, supporting the thesis of Sax et al10 of a multisystem SVD disorder.
Thore et al16 provided insights into the natural history of patho‐anatomical changes in brain small vessels with aging. They undertook a morphometric analysis of arteriolar tortuosity in human cerebral white matter of preterm, young, and aged subjects (age range 23 weeks postconception to 102 years). They used computerized morphometry to determine a vascular curl score (curvilinear length/straight length) in white matter arterioles in thick (100 μm) alkaline phosphatase–stained sections. They reported that the tortuosity score increased with age and showed borderline association with a history of IHD (P=0.058 for distribution).
In patients with acute subarachnoid hemorrhage, ECG changes including ST‐segment deviation and QT‐prolongation are common and an adverse prognostic factor.34 The extent and nature of the ECG changes correlate with vasospasm identified on cerebral arteriography.35 An increase in circulating troponin concentration is an adverse prognostic factor after subarachnoid hemorrhage.36 Although coronary tone has not been measured directly in patients with subarachnoid hemorrhage, these results implicate coronary vasospasm as a secondary process leading to myocardial ischemia in affected patients.
Mechanisms of SVD Affecting the Heart and Brain
We hypothesize that SVD is a multisystem disorder with a common pathophysiological basis that differentially affects the heart and brain in some patients. The natural history is incompletely understood. Why some patients with MVA subsequently develop vascular cognitive impairment and others do not is an unanswered question. Potential underpinning mechanisms include premature vascular aging, clustering of vascular risk factors leading to an accelerated cardiovascular risk, and activation of the endothelin system.9, 37 Vascular fibrosis driven by the transforming growth factor β family of regulatory signaling proteins may also be causally relevant.38
Premature Vascular Aging and Oxidative Stress
Vascular aging is associated with endothelial dysfunction,38 oxidative stress,38 increased blood vessel stiffness,39 impaired angiogenesis,40 rarefaction,41 and extracellular matrix changes.42 Degeneration and perivascular fibrosis in the microvasculature supplying cerebral periventricular white matter accumulate with age.43 Premature vascular aging may have a genetic component.44 Genetic susceptibility and interactions with environmental vascular factors (e.g., smoking, obesity, and lifestyle) may predispose to accelerated risk of clinical syndromes because of SVD in the heart and brain.
Systemic Endothelial Dysfunction
In the CorMicA study,45 we tested the hypothesis that patients with INOCA also have functional abnormalities in peripheral small arteries. Using arterioles isolated from gluteal biopsies, we found that patients with microvascular angina and vasospastic angina had peripheral microvascular abnormalities characterized by reduced maximum relaxation following incubation with ACh (in keeping with endothelial dysfunction) and increased responses to vasoconstrictor stimuli. Our study provides evidence of associations between coronary microvascular dysfunction and SVD in other organs, such as the brain and kidney.
Endothelial activation is mechanistically implicated in SVD secondary to hypertension and associated with changes in cognitive performance over time.46 Circulating molecules that are mediators of endothelial dysfunction are implicated in the pathophysiology of SVD, leading to angina and cognitive decline. A systematic review and meta‐analysis of circulating markers of inflammation (C‐reactive protein, tumor necrosis factor‐α, interleukin‐6) and endothelial dysfunction (notably homocysteine and von Willebrand factor) disclosed associations with lacunes, but not circulating markers of coagulation and fibrinolysis.47
Endothelin‐1
Endothelin‐1 is implicated in the vascular pathophysiology of SVD in the heart and brain (Figure 3). Endothelin‐1 is a 21‐amino acid peptide that is released mainly by endothelial cells.48 Endothelin‐1 is a highly potent vasoconstrictor via its ETA receptors expressed on vascular smooth muscle cells. In addition, this peptide has profibrotic, mitogenic, pro‐oxidant, pro‐inflammatory, and inotropic actions and regulates renal fluid and electrolyte homeostasis.48
Endothelin‐1 increases peripheral49 and coronary50 vascular tone via ETA‐activation.51 Endothelin‐1 contributes to coronary endothelial dysfunction,50 and its tonic inhibitory effect on myocardial perfusion, as revealed by positron emission tomography, is related to the presence and extent of risk factors for atherosclerosis.52 Kaski et al53 observed that in patients with MVA, circulating endothelin‐1 concentrations were increased and associated with a shorter time to onset of angina during exercise. In subsequent studies,54 they showed that increased endothelin‐1 activity is associated with reduced coronary flow responses, notably in women. Using rest/dipyridamole positron emission tomography with Rb‐82 for the assessment of IHD, Johnson et al55 identified an abnormal pattern of diffuse heterogeneous myocardial perfusion that was associated with coronary SVD. They observed that in patients with heterogeneous reductions in resting myocardial perfusion (consistent with coronary SVD), treatment with the ETA antagonist, darusentan, improved myocardial perfusion, and increased the homogeneity of the perfusion pattern. They concluded that in patients with coronary SVD, endothelin‐1 caused regional reductions in myocardial perfusion and that these abnormalities could be improved by ETA receptor blockade. In a randomized placebo‐controlled trial of an oral ETA antagonist (atrasentan, 10 mg PO daily) administered for 6 months in 47 patients with coronary microvascular disease, Reriani et al56 observed that chronic ETA antagonist therapy improved microvascular coronary endothelial function. This change was accompanied by greater reductions in mean arterial blood pressure and plasma glucose.56 Recent genetic fine mapping linked the endothelin gene, EDN1, to multiple cardiovascular disease states, including coronary heart disease, coronary calcification, migraine headache, cervical artery dissection, fibromuscular dysplasia, and hypertension.57 In the CorMicA study,45 peripheral arterioles isolated from patients with INOCA had enhanced vasoconstriction in response to ET‐1 and the thromboxane agonist U46619 compared with vasoconstrictor responses from control subjects. The results support the provocative concept that patients with INOCA are at risk of developing generalized SVD.
Future Directions
Many of the current studies have limitations, such as their cross‐sectional design and lack of longitudinal follow‐up. Age‐related changes may be a confounding factor in the associations between SVD in the heart and brain. Longitudinal studies of the pathological changes and risk factors with appropriate controls would help in better understanding the natural history of these conditions. For example, are patients with microvascular disease in the heart indeed more likely to develop vascular cognitive impairment? Potential therapeutic targets may emerge and the effects of endothelin‐1 receptor antagonists in cerebral SVD would be of interest.
Advances for Diagnosis, Treatment, and Epidemiology of SVD in the Heart and Brain
The positive results from the CorMicA study should be investigated further for external validity in a multicenter trial. Nuclear imaging with SPECT and positron emission tomography and cardiovascular MRI are highly informative for investigating ischemia in the heart and brain. Advances in cardiovascular MRI now enable quantitative measurements of myocardial blood flow (mL/min per g tissue) with pixel‐level resolution in near real‐time,58 which holds promise to be diagnostically useful for patients with INOCA with potentially a combinatory approach with advanced cardiovascular MRI in the heart and brain.
Advances in brain imaging to quantify SVD include diffusion imaging at 3.0 T, susceptibility‐weighted MRI (to detect cerebral microbleeds), T1‐weighted MRI (lacunes), fluid‐attenuated inversion recovery MRI (white matter hyperintensities), diffusion tensor imaging (white matter integrity), subcortical atrophy (3D‐T1‐weighted imaging), and brain arterial spin labeling to map regional cerebral blood flow with CO2 challenge to quantify cerebrovascular reactivity. Recent advances in brain imaging have evidenced the clinical significance of microbleeds, which are a biomarker for some manifestations of SVD. MRI at 7.0 T offers a number of novel insights into the arterial and parenchymal lesions associated with SVD.59 MRI at 7.0 T visualizes perforating arteries, cerebral micro‐infarcts, and lesions in the arterial walls. Future research using 7.0 T MRI of the brain in patients with cardiac SVD seems warranted.
Advances in Therapy
Preventive measures for SVD in at‐risk or affected individuals currently focus on modification of vascular risk factors, notably hypertension, obesity, and smoking. Lifestyle interventions, notably through regular aerobic exercise, are recommended.3, 4, 27 There are no targeted specific disease‐modifying therapies for SVD in the heart or brain, presenting a major opportunity for research and potential therapeutic intervention.3, 5, 6
Endothelin‐1 Receptor Antagonists
Endothelin‐1 receptor antagonists are an established treatment for microvascular disease in the lung; for example, they are a drug of choice for pulmonary arterial hypertension. Although they were thought to have renoprotective effects, the SONAR trial (ClinicalTrials.gov Identifier: NCT01858532; atrasentan phase 3 trial, diabetic nephropathy) closed early (Q4.2017) because of a lack of primary end‐point events in the study population. Two small randomized trials of an endothelin‐1 receptor antagonist in MVA55, 56 had favorable results, but these compounds are not available following “negative” phase 2/3 trials in oncology and hypertension. There were no safety concerns.
Rho Kinase Inhibitors
The RhoA/Rho kinase system plays an important role in vasoconstriction. RhoA/Rho kinase inhibitors have therapeutic potential for patients with MVA. A study of the effects of SAR407899 on coronary vasomotor function using coronary flow reserve in patients with MVA (NCT03236311) was halted early because of slow enrollment. This outcome reflects the need for future trials to adopt eligibility criteria and methods of assessment that facilitate enrollment.
Conclusion
Our review provides evidence that abnormalities in cerebral blood flow are common in patients with MVA and that SVD can be considered a multisystem disorder. Vascular risk factors alone cannot explain INOCA because many patients with MVA lack risk factors for vascular disease. Key gaps in knowledge include (1) the natural history and prognosis of multisystem SVD; (2) causal genetic variants; (3) underlying molecular mechanisms; (4) optimal diagnostic methods for SVD in heart, brain, and other organs; and (5) preventive and/or disease‐modifying therapy (pharmacological and nonpharmacological).
Sources of Funding
This work was supported by funding from the British Heart Foundation (BHF) (RE/18/6/6134217; PG/17/25/32884; FS/17/26/32744) and Alzheimer's Society (UK) (Project Ref 20140901).
Disclosures
C.B. is employed by the University of Glasgow, which holds consultancy and research agreements with companies that have commercial interests in the diagnosis and treatment of angina. The companies include Abbott Vascular, AstraZeneca, Boehringer Ingelheim, HeartFlow, Menarini Pharmaceuticals, Philips, and Siemens Healthcare. These companies had no involvement in this article. A.H.H. has funding from Alzheimer's Society (UK) and Alzheimer's Drug Discovery Foundation (Project Ref 20140901) to carry out a clinical trial of the PDE5 inhibitor drug tadalafil for possible use in SVD and A.C.P. is part of the study team. A.H.H. has received honoraria from Eli Lilly and from the National Institute on Aging. A.H.H. and R.M.T. are both members of the Dementia Platform UK vascular experimental medicine study group. The remaining authors have no disclosures to report.
Footnote
†
Dr Kaski and Dr Hainsworth are co‐senior authors.
Supplemental Material
Table S1. Relevant Articles Identified in Literature Review Not Relating to SVD in the Heart and Brain
- Download
- 116.31 KB
References
1.
GBD 2016 DALYs and HALE Collaborators . Global, regional, and national disability‐adjusted life‐years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990‐2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1260–1344.
2.
Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee . Heart disease and stroke statistics‐2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492.
3.
Bairey Merz CN, Pepine CJ, Walsh MN, Fleg JL. Ischemia and No Obstructive Coronary Artery Disease (INOCA): developing evidence‐based therapies and research agenda for the next decade. Circulation. 2017;135:1075–1092.
4.
Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018;104:284–292.
5.
Creager MA. The crisis of vascular disease and the journey to vascular health: presidential address at the American Heart Association 2015 Scientific Sessions. Circulation. 2016;133:2593–2598.
6.
Bosetti F, Galis ZS, Bynoe MS, Charette M, Cipolla MJ, Del Zoppo GJ, Gould D, Hatsukami TS, Jones TL, Koenig JI, Lutty GA, Maric‐Bilkan C, Stevens T, Tolunay HE, Koroshetz W; “Small Blood Vessels: Big Health Problems” Workshop Participants . “Small Blood Vessels: Big Health Problems?”: Scientific Recommendations of the National Institutes of Health Workshop. J Am Heart Assoc. 2016;5:e004389.
7.
Fulton WF. Arterial anastomoses in the coronary circulation. I. Anatomical features in normal and diseased hearts demonstrated by stereoarteriography. Scott Med J. 1963;8:420–434.
8.
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701.
9.
Horsburgh K, Wardlaw JM, van Agtmael T, Allan SM, Ashford MLJ, Bath PM, Brown R, Berwick J, Cader MZ, Carare RO, Davis JB, Duncombe J, Farr TD, Fowler JH, Goense J, Granata A, Hall CN, Hainsworth AH, Harvey A, Hawkes CA, Joutel A, Kalaria RN, Kehoe PG, Lawrence CB, Lockhart A, Love S, Macleod MR, Macrae IM, Markus HS, McCabe C, McColl BW, Meakin PJ, Miller A, Nedergaard M, O'Sullivan M, Quinn TJ, Rajani R, Saksida LM, Smith C, Smith KJ, Touyz RM, Trueman RC, Wang T, Williams A, Williams SCR, Work LM. Small vessels, dementia and chronic diseases—molecular mechanisms and pathophysiology. Clin Sci (Lond). 2018;132:851–868.
10.
Sax FL, Cannon RO III, Hanson C, Epstein SE. Impaired forearm vasodilator reserve in patients with microvascular angina. Evidence of a generalized disorder of vascular function? N Engl J Med. 1987;317:1366–1370.
11.
Brunelli C, Nobili F, Spallarossa P, Olivotti L, Rossettin P, Rodriguez G, Caponnetto S. Cerebral blood flow reserve in patients with syndrome X. Coron Artery Dis. 1996;7:587–590.
12.
Sun SS, Shiau YC, Tsai SC, Ho YJ, Wang JJ, Kao CH. Cerebral perfusion in patients with syndrome X: a single photon emission computed tomography study. J Neuroimaging. 2001;11:148–152.
13.
Lesnik Oberstein SA, Jukema JW, Van Duinen SG, Macfarlane PW, van Houwelingen HC, Breuning MH, Ferrari MD, Haan J. Myocardial infarction in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). Medicine (Baltimore). 2003;82:251–256.
14.
Pai PY, Liu FY, Kao A, Lin CC, Lee CC. A higher prevalence of abnormal regional cerebral blood flow in patients with syndrome X and abnormal myocardial perfusion. Jpn Heart J. 2003;44:145–152.
15.
Andin U, Gustafson L, Passant U, Brun A. A clinico‐pathological study of heart and brain lesions in vascular dementia. Dement Geriatr Cogn Disord. 2005;19:222–228.
16.
Thore CR, Anstrom JA, Moody DM, Challa VR, Marion MC, Brown WR. Morphometric analysis of arteriolar tortuosity in human cerebral white matter of preterm, young, and aged subjects. J Neuropathol Exp Neurol. 2007;66:337–345.
17.
Park SA, Cho KH, Kim NH, Yang CY, Park SH. SPECT myocardial perfusion in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Clin Nucl Med. 2013;38:e426–e428.
18.
Riverol M, Becker JT, Lopez OL, Raji CA, Thompson PM, Carmichael OT, Gach HM, Longstreth WT Jr, Fried L, Tracy RP, Kuller LH. Relationship between systemic and cerebral vascular disease and brain structure integrity in normal elderly individuals. J Alzheimers Dis. 2015;44:319–328.
19.
Yamamoto Y, Craggs LJ, Watanabe A, Booth T, Attems J, Low RW, Oakley AE, Kalaria RN. Brain microvascular accumulation and distribution of the NOTCH3 ectodomain and granular osmiophilic material in CADASIL. J Neuropathol Exp Neurol. 2013;72:416–431.
20.
Ong P, Camici PG, Beltrame JF, Crea F, Shimokawa H, Sechtem U, Kaski JC, Bairey Merz CN; Coronary Vasomotion Disorders International Study G . International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16–20.
21.
Patel MR, Peterson ED, Dai D, Brennan JM, Redberg RF, Anderson HV, Brindis RG, Douglas PS. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362:886–895.
22.
Tavella R, Cutri N, Tucker G, Adams R, Spertus J, Beltrame JF. Natural history of patients with insignificant coronary artery disease. Eur Heart J Qual Care Clin Outcomes. 2016;2:117–124.
23.
Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, Eteiba H, Shaukat A, Lindsay M, Robertson K, Hood S, McGeoch R, McDade R, Yii E, Sidik N, McCartney P, Corcoran D, Collison D, Rush C, McConnachie A, Touyz RM, Oldroyd KG, Berry C. Stratified medical therapy using invasive coronary function testing in angina: CorMicA Trial. J Am Coll Cardiol. 2018. Available at: http://www.onlinejacc.org/content/early/2018/09/12/j.jacc.2018.09.006. Accessed December 14, 2018.
24.
Jespersen L, Hvelplund A, Abildstrom SZ, Pedersen F, Galatius S, Madsen JK, Jorgensen E, Kelbaek H, Prescott E. Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events. Eur Heart J. 2012;33:734–744.
25.
McAleese KE, Alafuzoff I, Charidimou A, De Reuck J, Grinberg LT, Hainsworth AH, Hortobagyi T, Ince P, Jellinger K, Gao J, Kalaria RN, Kovacs GG, Kövari E, Love S, Popovic M, Skrobot O, Taipa R, Thal DR, Werring D, Wharton SB, Attems J. Post‐mortem assessment in vascular dementia: advances and aspirations. BMC Med. 2016;14:129.
26.
Sheikh AR, Wei J, Merz CDB, Beltrame JF. The current state of invasive coronary evaluation and management of patients with angina and nonobstructive coronary arteries. Available at: https://www.acc.org/latest-in-cardiology/articles/2016/05/26/08/31/the-current-state-of-invasive-coronary-evaluation-and-management-of-patients-with-angina-and-nonobstructive-coronary-arteries. Accessed December 7, 2018.
27.
Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB III, Kligfield PD, Krumholz HM, Kwong RY, Lim MJ, Linderbaum JA, Mack MJ, Munger MA, Prager RL, Sabik JF, Shaw LJ, Sikkema JD, Smith CR Jr, Smith SC Jr, Spertus JA, Williams SV; American College of Cardiology Foundation . 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:3097–3137.
28.
Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta‐analysis. BMJ. 2010;341:c3666.
29.
Bos D, Wolters FJ, Darweesh SKL, Vernooij MW, de Wolf F, Ikram MA, Hofman A. Cerebral small vessel disease and the risk of dementia: a systematic review and meta‐analysis of population‐based evidence. Alzheimers Dement. 2018;14:1482–1492.
30.
Bezerra DC, Sharrett AR, Matsushita K, Gottesman RF, Shibata D, Mosley TH Jr, Coresh J, Szklo M, Carvalho MS, Selvin E. Risk factors for lacune subtypes in the Atherosclerosis Risk in Communities (ARIC) Study. Neurology. 2012;78:102–108.
31.
Adib‐Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke. 2010;41:630–634.
32.
Makin SD, Cook FA, Dennis MS, Wardlaw JM. Cerebral small vessel disease and renal function: systematic review and meta‐analysis. Cerebrovasc Dis. 2015;39:39–52.
33.
Weidmann B, Jansen WC, Bock A, Assheuer J, Tauchert MO. Technetium‐99 m‐HMPAO brain SPECT in patients with syndrome X. Am J Cardiol. 1997;79:959–961.
34.
Sakr YL, Lim N, Amaral AC, Ghosn I, Carvalho FB, Renard M, Vincent JL. Relation of ECG changes to neurological outcome in patients with aneurysmal subarachnoid hemorrhage. Int J Cardiol. 2004;96:369–373.
35.
Ibrahim GM, Macdonald RL. Electrocardiographic changes predict angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2012;43:2102–2107.
36.
Naidech AM, Kreiter KT, Janjua N, Ostapkovich ND, Parra A, Commichau C, Fitzsimmons BF, Connolly ES, Mayer SA. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. 2005;112:2851–2856.
37.
Thompson CS, Hakim AM. Living beyond our physiological means: small vessel disease of the brain is an expression of a systemic failure in arteriolar function: a unifying hypothesis. Stroke. 2009;40:e322–e330.
38.
Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32:659–668.
39.
Huveneers S, Daemen MJ, Hordijk PL. Between Rho(k) and a hard place: the relation between vessel wall stiffness, endothelial contractility, and cardiovascular disease. Circ Res. 2015;116:895–908.
40.
Valcarcel‐Ares MN, Gautam T, Warrington JP, Bailey‐Downs L, Sosnowska D, de Cabo R, Losonczy G, Sonntag WE, Ungvari Z, Csiszar A. Disruption of Nrf2 signaling impairs angiogenic capacity of endothelial cells: implications for microvascular aging. J Gerontol A Biol Sci Med Sci. 2012;67:821–829.
41.
Faber JE, Zhang H, Lassance‐Soares RM, Prabhakar P, Najafi AH, Burnett MS, Epstein SE. Aging causes collateral rarefaction and increased severity of ischemic injury in multiple tissues. Arterioscler Thromb Vasc Biol. 2011;31:1748–1756.
42.
Sobin SS, Bernick S, Ballard KW. Histochemical characterization of the aging microvasculature in the human and other mammalian and non‐mammalian vertebrates by the periodic acid‐Schiff reaction. Mech Ageing Dev. 1992;63:183–192.
43.
Farkas E, de Vos RA, Donka G, Jansen Steur EN, Mihaly A, Luiten PG. Age‐related microvascular degeneration in the human cerebral periventricular white matter. Acta Neuropathol. 2006;111:150–157.
44.
Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard‐Herman M, Collins FS, Nabel EG, Cannon RO III, Gahl WA, Introne WJ. Phenotype and course of Hutchinson‐Gilford progeria syndrome. N Engl J Med. 2008;358:592–604.
45.
Ford TJ, Rocchiccioli P, Good R, McEntegart M, Eteiba H, Watkins S, Shaukat A, Lindsay M, Robertson K, Hood S, Yii E, Sidik N, Harvey A, Montezano AC, Beattie E, Haddow L, Oldroyd KG, Touyz RM, Berry C. Systemic microvascular dysfunction in microvascular and vasospastic angina. Eur Heart J. 2018. Available at: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehy529/5079248. Accessed December 14, 2018.
46.
Uiterwijk R, Huijts M, Staals J, Rouhl RP, De Leeuw PW, Kroon AA, Van Oostenbrugge RJ. Endothelial activation is associated with cognitive performance in patients with hypertension. Am J Hypertens. 2016;29:464–469.
47.
Wiseman S, Marlborough F, Doubal F, Webb DJ, Wardlaw J. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non‐lacunar stroke and non‐stroke: systematic review and meta‐analysis. Cerebrovasc Dis. 2014;37:64–75.
48.
Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ. Endothelin. Pharmacol Rev. 2016;68:357–418.
49.
Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, Webb DJ. Endothelin‐A receptor antagonist‐mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin‐B receptor blockade. Circulation. 1998;97:752–756.
50.
MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol. 2001;37:137–143.
51.
Halcox JP, Nour KR, Zalos G, Quyyumi AA. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res. 2001;89:969–976.
52.
Mather KJ, Lteif AA, Veeneman E, Fain R, Giger S, Perry K, Hutchins GD. Role of endogenous ET‐1 in the regulation of myocardial blood flow in lean and obese humans. Obesity (Silver Spring). 2010;18:63–70.
53.
Kaski JC, Elliott PM, Salomone O, Dickinson K, Gordon D, Hann C, Holt DW. Concentration of circulating plasma endothelin in patients with angina and normal coronary angiograms. Br Heart J. 1995;74:620–624.
54.
Cox ID, Botker HE, Bagger JP, Sonne HS, Kristensen BO, Kaski JC. Elevated endothelin concentrations are associated with reduced coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. J Am Coll Cardiol. 1999;34:455–460.
55.
Johnson NP, Gould KL. Physiology of endothelin in producing myocardial perfusion heterogeneity: a mechanistic study using darusentan and positron emission tomography. J Nucl Cardiol. 2013;20:835–844.
56.
Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon R, Rihal C, Lerman LO, Lerman A. Long‐term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation. 2010;122:958–966.
57.
Gupta RM, Hadaya J, Trehan A, Zekavat SM, Roselli C, Klarin D, Emdin CA, Hilvering CRE, Bianchi V, Mueller C, Khera AV, Ryan RJH, Engreitz JM, Issner R, Shoresh N, Epstein CB, de Laat W, Brown JD, Schnabel RB, Bernstein BE, Kathiresan S. A genetic variant associated with five vascular diseases is a distal regulator of endothelin‐1 gene expression. Cell. 2017;170:522–533.e15.
58.
Hsu LY, Groves DW, Aletras AH, Kellman P, Arai AE. A quantitative pixel‐wise measurement of myocardial blood flow by contrast‐enhanced first‐pass CMR perfusion imaging: microsphere validation in dogs and feasibility study in humans. JACC Cardiovasc Imaging. 2012;5:154–166.
59.
Benjamin P, Viessmann O, MacKinnon AD, Jezzard P, Markus HS. 7 Tesla MRI in cerebral small vessel disease. Int J Stroke. 2015;10:659–664.
Information & Authors
Information
Published In
Copyright
© 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
History
Published online: 2 February 2019
Published in print: 5 February 2019
Keywords
Notes
J Am Heart Assoc. 2019;8:e011104. https://doi.org/10.1161/JAHA.118.011104.
Authors
Funding Information
British Heart Foundation: RE/13/5/30177, PG/17/25/32884, FS/17/26/32744
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Paying Homage to Microvessel Remodeling and Small Vessel Disease in Neurodegeneration: Implications for the Development of Late-Onset Alzheimer’s Disease, Journal of Vascular Diseases, 3, 4, (419-452), (2024).https://doi.org/10.3390/jvd3040033
- Clinical Phenotypes Associated With Cerebral Small Vessel Disease, Neurology, 103, 8, (2024).https://doi.org/10.1212/WNL.0000000000209919
- Association Between Cerebral Microbleeds and Neurological Outcomes in Patients Who Underwent Extracorporeal Membrane Oxygenation, Journal of the American Heart Association, 13, 20, (2024)./doi/10.1161/JAHA.124.037029
- Nomogram models for predicting myocardial ischemia under high altitude exposure: a cohort study, Scientific Reports, 14, 1, (2024).https://doi.org/10.1038/s41598-024-79735-y
- Altitude illnesses, Nature Reviews Disease Primers, 10, 1, (2024).https://doi.org/10.1038/s41572-024-00526-w
- Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease, Nature Reviews Cardiology, 21, 8, (556-573), (2024).https://doi.org/10.1038/s41569-024-01001-5
- Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden, Nature Reviews Cardiology, 21, 6, (379-395), (2024).https://doi.org/10.1038/s41569-023-00962-3
- Comparative evaluation of trypsin and elastase digestion techniques for isolation of murine retinal vasculature, Microvascular Research, 154, (104682), (2024).https://doi.org/10.1016/j.mvr.2024.104682
- Evaluating retinal blood vessels for predicting white matter hyperintensities in ischemic stroke: A deep learning approach, Journal of Stroke and Cerebrovascular Diseases, 33, 12, (108070), (2024).https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.108070
- Associations of cardiac function and arterial stiffness with cerebrovascular disease, International Journal of Cardiology, 407, (132037), (2024).https://doi.org/10.1016/j.ijcard.2024.132037
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.